Genomic Health has launched RxPONDER S1007, a breast cancer clinical trial being led by SWOG, one of the National Cancer Institute’s (NCI) cancer cooperative groups. The trial is designed to determine the effect of chemotherapy in breast cancer patients with one to three positive nodes who have a Recurrence Score (RS) result equal to, or less than, 25 as determined by the Oncotype DX breast cancer test.
Researchers will utilize the Oncotype DX breast cancer test to quantify each patient's individual risk of recurrence in order to assign them to the appropriate treatment. Women who have tumors with a RS result equal to, or less than, 25, the primary study group, will be randomized to receive hormonal therapy with or without chemotherapy. Women who have tumors with a high RS, greater than 25, will be offered chemotherapy plus hormonal therapy as standard of care, or in the context of other clinical studies.
While the trial is being led by SWOG, it is expected to be opened by the other major cooperative groups as well, giving patients wide access to the trial throughout the world.